0001104659-23-111596.txt : 20231026 0001104659-23-111596.hdr.sgml : 20231026 20231026070055 ACCESSION NUMBER: 0001104659-23-111596 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231026 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231026 DATE AS OF CHANGE: 20231026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 231347438 BUSINESS ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 tm2329192d1_8k.htm FORM 8-K
0001597264 false 0001597264 2023-10-26 2023-10-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): October 26, 2023

 

 

 

Blueprint Medicines Corporation

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37359   26-3632015

(State or other jurisdiction

of incorporation)

   (Commission File Number)   (I.R.S. Employer
Identification No.)

 

45 Sidney Street

Cambridge, Massachusetts

   02139
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (617) 374-7580

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class Trading symbol(s) Name of each exchange on which
registered
Common stock, par value $0.001 per share BPMC Nasdaq Global Select Market

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On October 26, 2023, Blueprint Medicines Corporation announced its financial results for the quarter ended September 30, 2023 and other business highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

 

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01  Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibit relating to Item 2.02 of this Form 8-K shall be deemed to be furnished and not filed:

 

Exhibit
No. 		   Description 
99.1   Press release issued by Blueprint Medicines Corporation on October 26, 2023
104    Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101) 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BLUEPRINT MEDICINES CORPORATION
   
Date: October 26, 2023 By:

/s/ Kathryn Haviland

    Kathryn Haviland
    Chief Executive Officer

 

 

 

 

 EX-99.1 2 tm2329192d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Blueprint Medicines Reports Third Quarter 2023 Results

 

-- Achieved $54.2 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues, representing 90% growth year-over-year, and $56.6 million in total revenues in the third quarter of 2023 –

 

-- Approximately 800 patients on AYVAKIT in the U.S. at the end of the third quarter, more than 35% growth in treated patients quarter-over-quarter and driven by ISM --

 

-- Plan to present data from Part 1 of the HARBOR trial of elenestinib in ISM at ASH 2023 –

 

CAMBRIDGE, Mass., Oct 26, 2023 – Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the third quarter ended September 30, 2023.

 

“In the first full quarter following AYVAKIT’s launch in indolent systemic mastocytosis, we saw strong and steady growth in both patients treated and revenue, reflecting a highly favorable reception to AYVAKIT’s unique and compelling clinical profile and the effectiveness of our ongoing efforts to bring AYVAKIT to all patients who can benefit from treatment,” said Kate Haviland, Chief Executive Officer at Blueprint Medicines. “Through the end of this year and into 2024, we anticipate continued steady growth in AYVAKIT revenue driven by both existing and new prescribers as we execute a disciplined approach to managing operating expenses and allocating capital to our most important investments.”

 

Third Quarter 2023 Highlights and Recent Progress

 

Systemic mastocytosis (SM) and other mast cell disorders

 

·Third quarter AYVAKIT net revenue grew 90 percent year-over-year to $54.2 million, with $49.1 million coming from the U.S, in the first full quarter of ISM launch.

 

Upcoming 2023 Milestones

 

Blueprint Medicines plans to achieve the following milestones by the end of 2023:

 

·Present data from Part 1 of the HARBOR trial of elenestinib in indolent SM at the American Society of Hematology conference in December 2023.

 

Third Quarter 2023 Results

 

·Revenues: Revenues were $56.6 million for the third quarter of 2023, including $54.2 million of net product revenues from sales of AYVAKIT/AYVAKYT and $2.4 million in collaboration revenues. Blueprint Medicines recorded revenues of $65.9 million in the third quarter of 2022, including $28.6 million of net product revenues from sales of AYVAKIT/AYVAKYT and $37.3 million in collaboration and license revenues.
·Cost of Sales: Cost of sales was $2.8 million for the third quarter of 2023, as compared to $3.0 million for the third quarter of 2022. The decrease was primarily due to a decrease in the cost of collaboration-related sales.
·R&D Expenses: Research and development expenses were $110.3 million for the third quarter of 2023, as compared to $128.0 million for the third quarter of 2022. This decrease was primarily due to a focused approach towards optimizing operational efficiency across our portfolio as we execute across our top priority programs and the timing of manufacturing of clinical trial materials. Research and development expenses included $11.2 million in stock-based compensation expenses for the third quarter of 2023.
·SG&A Expenses: Selling, general and administrative expenses were $70.7 million for the third quarter of 2023, as compared to $57.6 million for the third quarter of 2022. This increase was primarily due to an increase in compensation and personnel related costs driven by our first quarter field force expansion to support the AYVAKIT launch in ISM. Selling, general, and administrative expenses included $11.9 million in stock-based compensation expenses for the third quarter of 2023.

 

 

 

 

·Net Loss: Net loss was $133.7 million for the third quarter of 2023, or a net loss per share of $2.20, as compared to a net loss of $133.2 million for the third quarter of 2022, or a net loss per share of $2.23.
·Cash Position: As of September 30, 2023, cash, cash equivalents and investments were $827.2 million, as compared to $1,078.5 million as of December 31, 2022. Our cash and investments provide a durable capital position which enables us to reach a self-sustainable profile.

 

Conference Call Information

 

Blueprint Medicines will host a live conference call and webcast at 8:00 a.m. ET today to discuss third quarter 2023 financial results and recent business activities. The conference call may be accessed by dialing 833-470-1428 (domestic) and referring to conference ID 368229. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

 

Upcoming Investor Conferences

 

Blueprint Medicines will participate in the following upcoming investor conferences:

 

·Stifel Healthcare Conference on Wednesday, November 15, 2023 at 12:40 pm ET.

 

A live webcast of this presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.

 

About Blueprint Medicines

 

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we have brought our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for mast cell disorders, including systemic mastocytosis and chronic urticaria, breast cancer and other cancers vulnerable to CDK2 inhibition, as well as EGFR-mutant lung cancer. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

 

 

 

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for Blueprint Medicines’ current or future approved drugs and drug candidates; the potential benefits of any of Blueprint Medicines’ current or future approved drugs or drug candidates in treating patients; and Blueprint Medicines' financial performance, strategy, goals and anticipated milestones, business plans and focus. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation: preliminary activity and safety data may not be representative of more mature data; the risk of delay of any current or planned clinical trials or the development of Blueprint Medicines' current or future drug candidates; risks related to Blueprint Medicines' ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; preclinical and clinical results for Blueprint Medicines' drug candidates may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; the timing of the initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates may be delayed or slower than anticipated; actions of regulatory agencies may affect the initiation, timing and progress of clinical trials; the success of Blueprint Medicines' current and future collaborations, financing arrangements, partnerships or licensing arrangements may impact Blueprint Medicines’ ability to capitalize on the market potential of its approved drugs and drug candidates; and risks related to Blueprint Medicines' ability to obtain, maintain and enforce patent and other intellectual property protection for its products and current or future drug candidates it is developing. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.

 

Trademarks

 

Blueprint Medicines, AYVAKIT, AYVAKYT and associated logos are trademarks of Blueprint Medicines Corporation.

 

 

 

 

Blueprint Medicines Corporation

Selected Condensed Consolidated Balance Sheet Data

(in thousands)

(unaudited)

 

   September 30,   December 31, 
   2023   2022 
Cash, cash equivalents and marketable securities  $827,226   $1,078,472 
Working capital (1)   610,788    863,417 
Total assets   1,105,299    1,349,902 
Liability related to the sale of future royalties and revenues (2)   440,147    430,330 
Term loan (2)   238,378    139,083 
Deferred revenue (2)   8,010    18,291 
Total liabilities   902,688    835,225 
Total stockholders’ equity   202,611    514,677 

 

(1)Blueprint Medicines defines working capital as current assets less current liabilities.
(2)Amounts include both current and non-current portions of the balances.

 

 

 

 

Blueprint Medicines Corporation

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except per share data)

(Unaudited)

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
Revenues:                
Product revenue, net  $54,228   $28,634   $133,173   $80,929 
Collaboration and license revenue   2,338    9,843    44,250    56,826 
License revenue – Related Party   -    27,500    -    27,500 
Total revenues   56,566    65,977    177,423    165,255 
Cost and operating expenses:                    
Cost of sales   2,782    3,000    8,280    12,965 
Collaboration loss sharing   1,771    1,665    4,301    7,076 
Research and development   110,252    127,981    330,184    359,579 
Selling, general and administrative   70,741    57,608    215,826    173,354 
Total cost and operating expenses   185,546    190,254    558,591    552,974 
Other income (expense):                    
Interest expense, net   (3,808)   (8,396)   (13,624)   (7,527)
Other income (expense), net   (728)   396    (369)   575 
Total other expense   (4,536)   (8,000)   (13,993)   (6,952)
Loss before income taxes   (133,516)   (132,277)   (395,161)   (394,671)
Income tax expense   197    886    907    4,200 
Net loss  $(133,713)  $(133,163)  $(396,068)  $(398,871)
Net loss per share - basic and diluted  $(2.20)  $(2.23)  $(6.55)  $(6.70)
Weighted-average number of common shares used in net loss per share - basic and diluted   60,688    59,758    60,445    59,564 

 

Media Contact 

Sarah Mena Guerrero 

617-714-6684 

media@blueprintmedicines.com

 

Investor Contact 

Jenna Cohen 

857-209-3147 

ir@blueprintmedicines.com

 

 

 

 

 EX-101.SCH 3 bpmc-20231026.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 bpmc-20231026_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 bpmc-20231026_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 26, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 26, 2023
Entity File Number 001-37359
Entity Registrant Name Blueprint Medicines Corporation
Entity Central Index Key 0001597264
Entity Tax Identification Number 26-3632015
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 45 Sidney Street
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code 617
Local Phone Number 374-7580
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol BPMC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 tm2329192d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001597264 2023-10-26 2023-10-26 iso4217:USD shares iso4217:USD shares 0001597264 false 8-K 2023-10-26 Blueprint Medicines Corporation DE 001-37359 26-3632015 45 Sidney Street Cambridge MA 02139 617 374-7580 false false false false false Common stock, par value $0.001 per share BPMC NASDAQ EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( !LX6E<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " ;.%I7Q:P'RNX K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)VEQ#Z';B^))07!!\1:2V=U@\X=DI-VW-ZV[740?P&-F?OGF M&YA.1ZE#PN<4(B:RF&\F-_@L==RR(U&4 %D?T:EG;-?4.([UV"ZYLH. MZ?'EV7=ROI, MRFLLO[*5=(JX99?)K^W=_>Z!]0UOVDKPJMGLA)"621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M !LX6E?PO*ZA1P0 (40 8 >&PO=V]R:W-H965T&UL MG9AM;^HV%,>_BI5-TR:5)@Y/;0=(E+8;NI>6E6Y7VK07)C%@-;$SVRGEV^\X MT(3=&T[0WI0\G7]^/C[Y'[N#K=*O9L.Y)>]I(LW0VUB;W?B^B38\9>9295S" MG972*;-PJM>^R31G<1&4)GX8!#T_94)ZHT%Q;:Y' Y7;1$@^U\3D:#C*WY@MO?L[F&,[]4B47*I1%*$LU70V],;V[#C@LH MGOA#\*TY.B9N*$NE7MW)-!YZ@2/B"8^LDV#P\\8G/$F<$G#\ZP./C M#_6'8O PF"4S?**2+R*VFZ%WY9&8KUB>V&>U_94?!M1U>I%*3/&7;/?/=CH> MB7)C57H(!H)4R/TO>S\DXCB G@@(#P%AP;U_44%YQRP;#;3:$NV>!C5W4 RU MB 8X(=VL+*R&NP+B[&BBWK@>^!:DW 4_.H3=[L/"$V%/D;TD8>^"A$'8_F^X M#P0E1EABA(5>&\,@?XV7QFJ8J+_KB/8*G7H%5[TW)F,1'WI0GH;K-^Z-?OB. M]H*?$;YVR=?&U$=W*LJA%BUYV66\#@X/OVI]0B Z)40'51D#05Q0/"1L74>! MQZ]88CC"T2TYNN"^ML#OR(!). M'O-T65_;N$80T%:[W^Y>(SS]DJ=_#L\S7PM7V9"S1Y;6)@K7N4URGFD!\3,> MBPCN&C)1.E.:.7-#2*]*TJMS2" SF.8[!&<_%Q0#[#<^1)UI/ADITN M68A8\AV,54/WP3BK+D!1$_^&<^+.((LO:BMK&7&Y"4N76L1KS/1HU0(H;N)? MPY5S/-?J3+._C7:7!D+'_&?(CM=>+AB$-(V9H"T:A84 M]_AB#L>P8CR-@@OT:!\#J5H#Q7W]LXH@)_.-DEAO:!!I]SNM?OG51>@N'DO5 +MQ0JY)C,H;RU84LN#JS3R M5/9/<;>>:]Z*(#T%S4CT>D$RILD; M@P4)^3ZXA%Y/,ABNV3"-8A_M!'#3?M$L=N6WV*5+55M\#0*W\]D$(ZD,/\3- M^2-CY/X]VC"YYB<7;PU"C^/%W?@WC*ER^O LI[]/N5Z[+/T""G;C'"1CLGYN M_^>FP#_:5+H-^HRY-QJ2\!4(!9=]<&V]W_/N3ZS*BGWF4EG8M1:'&\[@6W / MP/V54O;CQ&U=R_\\C/X%4$L#!!0 ( !LX6E>?H!OPL0( .(, - M>&PO9KEMWDOSAR+DCO9*ZW="C<\W[ M)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3 M;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@ M:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_& M%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V M_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUS MS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D M^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>P MSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0 M_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^& M<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8 M[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( !LX6E>7BKL< MP !," + 7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$ M^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8E MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G%C:^?VZH:TE[VE-S9NMQ=%A?BTX'H ME'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L,9KD8 MM;:X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU75Z( M\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M>CR# M+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HD<%U M!D.LL8DF"=9#;E9T!N[RZ .;O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0 ( !LX6E&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S , MA:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@ MMO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*< M//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P M6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04 " ;.%I7 M99!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\2 M95LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&P MZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5 M,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*I ML0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U M[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ M 5!+ 0(4 Q0 ( !LX6E<'04UB@0 +$ 0 " 0 M !D;V-0&UL4$L! A0#% @ &SA:5\6L!\KN *P( M !$ ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% M @ &SA:5YE&PO=V]R:W-H965T&UL4$L! A0#% M @ &SA:5Y^@&_"Q @ X@P T ( !B@P 'AL+W-T>6QE M&PO=V]R:V)O;VLN>&UL4$L! A0#% @ M&SA:5R0>FZ*M ^ $ !H ( !KQ$ 'AL+U]R96QS+W=O M9(9 0 SP, !, M ( !E!( %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& D ,"0 ^ @ WA, end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://blueprintmedicines.com/role/Cover Cover Cover 1 false false All Reports Book All Reports bpmc-20231026.xsd bpmc-20231026_lab.xml bpmc-20231026_pre.xml tm2329192d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2329192d1_8k.htm": { "nsprefix": "BPMC", "nsuri": "http://blueprintmedicines.com/20231026", "dts": { "schema": { "local": [ "bpmc-20231026.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "bpmc-20231026_lab.xml" ] }, "presentationLink": { "local": [ "bpmc-20231026_pre.xml" ] }, "inline": { "local": [ "tm2329192d1_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://blueprintmedicines.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2329192d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2329192d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://blueprintmedicines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001104659-23-111596-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-111596-xbrl.zip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end